Healthcare Industry News: Trichomoniasis
News Release - August 27, 2013
BD ProbeTec(TM) Trichomonas vaginalis Q(x) Assay Launches on the BD Viper(TM) System with XTR(TM) Technology in the United StatesNew Molecular Test Available to Diagnose Trichomonas vaginalis in Asymptomatic and Symptomatic Females
BALTIMORE, Aug. 27, 2013 -- (Healthcare Sales & Marketing Network) -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration clearance and launch of the BD ProbeTec™ Trichomonas vaginalis Qx Amplified DNA Assay for the direct qualitative detection of T. vaginalis DNA in endocervical and vaginal samples as well as neat urine specimens to aid in the diagnosis of Trichomoniasis on the BD Viper™ System with XTR™ Technology. This assay has been CE-marked to the In Vitro Diagnostic Directive (98/79/EC).
Trichomoniasis is the most common curable sexually transmitted infection (STI). Worldwide, more than 180 million cases are estimated to occur annually.[i] Genital inflammation caused by Trichomoniasis can increase a woman's susceptibility to HIV infection. In HIV-infected women, Trichomoniasis may increase the likelihood of HIV transmission to sex partners. Furthermore, Trichomoniasis is often asymptomatic. For these reasons, experts recommend screening for T. vaginalis in women considered to be at high risk for infection (i.e., women who have new or multiple partners, have a history of STIs, exchange sex for payment, or use injection drugs).
"The global prevalence of Trichomoniasis is on the rise and there are more asymptomatic cases than previously thought," said Chris Demiris, Worldwide Group Marketing Manager, BD Diagnostics – Diagnostic Systems, Women's Health and Cancer. "The availability of an automated platform is especially important as clinical and public health communities embrace the need for a test that provides timely and accurate diagnosis of Trichomoniasis when screening high-risk populations."
The BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay is designed for use with the BD Viper System. Automated DNA extraction and simultaneous amplification and detection maximize laboratory efficiency and quality of results. Compared to wet mount microscopy and culture, the BD ProbeTec Trichomonas vaginalis Qx Assay reduces human intervention and associated variables and improves speed to results. The BD Viper System allows laboratories to test samples in panel mode for T. vaginalis, C. trachomatis and N. gonorrhea or in batch mode for chlamydia and gonorrhea, trichomonas and herpes on the same automated platform.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
[i] Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):6-10.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBD receives FDA Approval for HPV Test with Extended Genotyping Capabilities
BD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation
BD Launches Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes, Dramatically Expanding Access to COVID-19 Testing